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Background: Cancers have become one of the most lethal diseases in elders. In traditional Chinese
medicine, Tan-Chih-Hsiao-Yao-San (TCHYS) and Long-Daan-Shiah-Gan-Tang (LDSGT) are used to treat
cancers. However, the growth-inhibitory effects and gene expression proﬁles of these drugs on cancer
cells are still unclear.
Methods: This study assessed the effects of TCHYS and LDSGT on viability of liver and bladder tumor cells,
and bladder TCCSUP cells were further subjected to proﬁle gene expression patterns with microarray
technology for identifying gene candidates that may be involved in the tumorigenesis.
Results: The results revealed that both drugs signiﬁcantly eliminated the growth of Chang liver and three
hepatoma cells. On the contrary, the embryonic liver WRL68 cells showed less response to the treat-
ments, whereas the control agent genistein had much higher inhibitory effect in WRL68 cells than in the
other hepatoma cells. Both TCHYS and LDSGT, as well as cisplatin and paclitaxel, exhibited dose-
dependent suppression on the viability of all bladder cancer cells. To characterize the possible regulation
for such effects, the proﬁling of gene expression was performed with complementary DNA chips. When
bladder transitional cell carcinoma (TCC) TCCSUP cells were treated with TCHYS, 29 upregulated and 28
downregulated genes were detected; whereas 54 genes were upregulated in the same cells treated with
LDSGT. Moreover, the detected gene expression patterns were also conﬁrmed by using the reverse
transcription-polymerase chain reaction assay.
Conclusion: This study initiates the evaluations of drug efﬁcacies and gene expression proﬁles of tradi-
tional Chinese medicines, which may provide important information and identify useful biomarkers for
treating cancers.
Copyright  2011, Taiwan Society of Geriatric Emergency & Critical Care Medicine. Published by Elsevier
Taiwan LLC. All rights reserved.1. Introduction
Aging involves a complex physiologic process that may lead to
increased susceptibility to cancers and other diseases1,2. An articleof Biochemical Science and
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iwan Society of Geriatric Emergeninvestigated the male-to-female incidence rate ratios for speciﬁc
cancer sites and histologies for the period from 1975 to 2004 and
found that urinary bladder cancer and hepatocellular carcinoma
(HCC) (aged 40e59 years) are two of the largest increases of
cancers3. Although surgical and chemotherapeutic procedures are
the routine treatment approaches,many cancer patients in different
stages of disease have selected treatment with alternative medi-
cines, because there are numerous successful cases of prescribing
traditional Chinese medicine (TCM) to treat cancer patients that
result in substantial health improvements4,5. The clinical practice
and therapeutic theory of TCM are completely different from those
of Western medicine. Accordingly, the doctors of Chinese medicine
select the appropriate herbal formulas for treating patients,
after considering holistically patients’ constitution, predisposition,cy & Critical Care Medicine. Published by Elsevier Taiwan LLC. All rights reserved.
Effects of TCHYS and LDSGT on Tumor Cells 31stamina, as well as their physical and mental strengths against the
illness. For hundreds of years, if not thousands, several kinds of
traditional Chinese herbal formulas or TCM have been recom-
mended for treating disease symptoms similar to cancers in China,
Taiwan, and the Chinese-populated countries/regions. In particular,
Tan-Chih-Hsiao-Yao-San (TCHYS) and Long-Daan-Shiah-Gan-Tang
(LDSGT) are two of the most well known and popular herbal
formulas used for treating cancers of liver, kidney, and bladder
origins6. However, patients who have been taking anticancer herbal
medicines for a long time may also develop some side effects with
different levels of severity7. Moreover, the efﬁcacies of these
frequently prescribed medicines like TCHYS and LDSGT have never
been conﬁrmed with themodern biomedical methodology, and the
complexity of TCM formulas containingmany constituents makes it
very difﬁcult to standardize the preparation of the herbal products.
For years, many laboratories worldwide have participated in the
isolation of pure and bioactive chemical compounds from herb
mixture-decocted extracts8. They anticipated the identiﬁcation of
similar or identical compounds from the functional-related herbal
medicines so that the historical medicinal theory of “curing
a disease with the administration of different Chinese herbal
medicines” may be conﬁrmed; however it seems not the case. We
believe that the investigation of the molecular regulatory pathways
in cells is the key to elucidating efﬁcacies of herbal drugs, because
different herbs blended and decocted together may produce many
unaccountable bioactive compounds, but they may only exert their
activity through the limited numbers of genes or molecular path-
ways in vivo. Therefore, the original intention was to use functional
genomic technology to assess gene expression patterns in a variety
of tumor cell lines treated with two clinical application-alike
Chinese herbal drugs, TCHYS and LDSGT, both of which have been
suggested to be anticancer.
Aging increases incidence of cancers and TCM is used for a long
time to treat cancers. Because CHYS and LDSGT are commonly
prescribed TCMs used for promoting health; their safety has been
accepted for decades. Therefore, those regimensmay be beneﬁcial to
the elderly with cancers who may not tolerate toxic regimens. The
present study uses the cell linemodel to test the effects of TCHYS and
LDSGT on inhibiting the growth of liver and bladder tumors, which
have been reported to be susceptible to drug treatments clinically,
and compare with those exerted by the modern anticancer agents
such as genistein, cisplatin, and paclitaxel. Because both TCMs
showed promising efﬁcacies on all bladder transitional cellTable 1
Component herbs of TCHYS and LDSGT
Drugs Component herbs/amounts E
TCHYS Baishaoyao (Paeoniae lactiﬂora)/4 g
Baizhu (Atractylodis macrocephalae)/4 g
Chaihu (Bupleurum chinense)/4 g
Danggui (Angelicae sinensis)/4 g
Fuling (Poria cocoa)/4 g
Ginger root (Zingiber ofﬁcinale)/4 g
Mudanpi (Moutan radicis)/2.5 g
Peppermin (Mentha haplocalyx)/2 g
Shanzhi (Gardenia jasminoides)/2.5 g
Zhigancao (Glycyrrhizae praeparatae)/2 g
T
e
5
LDSGT Chaihu (B chinense)/4 g
Cheqianzi (Semen plantaginis)/2 g
Danggui (A sinensis)/2 g
Huangqin (Scutellaria baicalensis)/2 g
Longdancao (Gentiana scabra)/4 g
Mutong (Caulis akebiae)/2 g
Shanzhi (G jasminoides)/2 g
Shengdihuang (Rehmania glutinosa)/2 g
Shenggancao (Glycyrrhiza uralensis)/2 g
Zexie (Rhizoma alismatis)/4 g
T
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6carcinoma (TCC) cell lines tested, bladder TCCSUP cell line was
further subjected to proﬁle gene expression patterns with micro-
array technology, which resulted in identifying many gene candi-
dates that may be involved in the tumorigenesis of urothelial cell
carcinoma. In summary, the signiﬁcance of this study is to initiate the
systematic and scientiﬁc evaluations of TCM, whose molecular and
cellular bases of treating human diseases remain largely unknown.
2. Materials and Methods
2.1. Materials and herbal drug preparations
Molecular biological enzymes were mainly purchased from
Stratagene (La Jolla, CA, USA) unless otherwise speciﬁed, whereas
standard chemicals and reagents were obtained from Sigma (St.
Louis, MO, USA). All reagents were used according to the recom-
mendations of the manufacturers. Both TCHYS and LDSGT extracts
were prepared and provided by Koda Pharmaceutics, Ltd (Taoyuan,
Taiwan), a pharmaceutical company that conforms to Good
Manufacturing Practice and is approbated by the Taiwan govern-
ment. The herbal formulas and their preparation protocols are
described in Table 1. When preparing LDSGT, Mutong (Caulis ake-
biae, Koda Pharmaceutics), but not Guamutong (Aristolochia man-
shuriensis Kom, Koda Pharmaceutics), was used so as to avoid
possible toxicity of aristolochic acid that is produced by incorrect
processing of Guamutong9,10. Three other anticancer compounds,
genistein, cisplatin (PLATINOL-AQ, Bristol Myers Oncology, Prince-
ton, NJ), and paclitaxel (TAXOL, Bristol Myers Oncology), were also
used for comparative studies. The stock solution of genistein
(Sigma, St Louis, MO, USA, 50 mM) was prepared in pure DMSO
(Sigma) and was later diluted to the appropriate concentrations
with Dulbecco's Modiﬁed Eagle medium (DMEM) before use. The
other two drugs were produced by the same pharmaceutical
company (Bristol-Myers Squibb Co, New York, NY, USA), and made
as aqueous reagents. All the above drugs (TCHYS, LDSGT, genistein,
cisplatin, and paclitaxel) and diluting solvents (DMSO, water, and
cell culture media) were prepared and handled under the endo-
toxin-free environment in our laboratories.
2.2. Cells and cell culture
Five human liver cell lines, including one Chang Liver cell line,
three HCC (equal to hepatoma) HA22T/VGH, Hep3B and HepG2 cellxtraction processes
he herb mixtures (total weight of 33 g) were decocted under the endotoxin-free
nvironment with 1.5 L of water to produce 7 g of extract paste containing
7.3% moisture.
he herb mixtures (total weight of 26 g) were decocted under the endotoxin-free
nvironment with 1.5 L of water to produce 5 g of extract paste containing
6.1% moisture.
Table 2
Alternations in gene expression levels in TCCSUP cells treated with TCHYS
Genes for Gene products Hs.ID Acc. No Biological functions
Upregulated genes
1. AHCYL1 S-Adenosylhomocysteine hydrolase-like 1 Hs.4113 AA179513 One-carbon compound
metabolic process
2. AKAP1 A kinase (Adenosine 50 monophosphate-activated
protein kinase, PRKA) anchor protein 1
Hs.78921 R37961 RNA/protein binding
3. AOP2 Antioxidant protein 2 Hs.120 T65419 (1) Lipid catabolism
(2) Oxidative stress
4. BCR Breakpoint cluster region Hs.234799 R51875 (1) Signal transduction
(2) Protein phosphorylation
5. BRCA2 homolog EST1669, highly similar to BRCA2 NA NA NA
6. CCNE Cyclin E NA NA (1) Cell cycle
(2) Cell division
7. CEBPG CCAAT/enhancer binding
protein (C/EBP), gamma
Hs.2227 AA179189 (1) Differentiation
(2) Transcription
8. E2F4 E2F transcription factor 4, p107/p130-binding Hs.108371 R59900 Transcription
9. EIF4B Eukaryotic translation initiation factor 4B Hs.93379 AA173296 Regulation of translation
10. ELK1 ELK1 NA NA Regulation of transcription
11. EPRS Glutamyl-prolyl-tRNA synthetase Hs.55921 T47357 tRNA aminoacylation
12. ESTs 4002 NA Hs.79308 R51324 NA
13. ESTs Weakly similar to alternatively spliced
product using exon 13A
NA NA NA
14. ESTs 6051 NA Hs.164352 T57042 NA
15. HERC1 HECT and RCC1 (CHC1)-like domain 1 Hs.76127 AA181680 (1) Protein modiﬁcation
(2) Transport
16. HMGCR 3-Hydroxy-3-methylglutaryl-coenzyme
A reductase
Hs.11899 R51541 (1) Biosynthetic process
(2) Development
(3) Oxidation reduction
17. IRF-6 IRF-6 Hs.11801 NA NA
18. MLN62 MLN62 NA NA (1) Apoptosis
(2) Development
(3) Signal transduction
19. NA6106 NA6106 NA AA063310 NA
20. NUP210 KIAA0906 protein Hs.56966 R37724 (1) Transport
(2) Translocation
21. PKIA homolog ESTs, highly similar to PKIA Hs.3407 NA NA
22. RALBP1 RalA binding protein 1 Hs.75447 AA085619 GTPase activator
23. RCN1 Reticulocalbin 1 Hs.167791 AA114081 Calcium ion binding
24. RPL27 Ribosomal protein L27 Hs.111611 AA190881 Translational elongation
25. SLC16A1 Solute carrier family 16 (monocarboxylic
acid transporters), member 1
Hs.75231 R49543 Transport
26. SOX22 SRY (sex-determining region Y)-box 22 Hs.43627 AA283123 Transcription
27. TNNI2 Troponin I, skeletal, fast Hs.83760 AA181380 Transcription
28. UBE2H Ubiquitin-conjugating enzyme E2H Hs.28505 N35796 Protein ubiquitination
29. UBXD2 KIAA0242 protein Hs.77495 H10657 Response to unfolded protein
Downregulated genes
30. C4A Complement component 4A Hs.170250 R37128 Complement activation
31. COH1 KIAA0532 protein Hs.21077 R37311 NA
32. CRABP1 Cellular retinoic acid-binding protein 1 Hs.7678 W95693 (1) Development
(2) Signal transduction
(3) Transport
33. DLX4 Distal-less homeobox 4 Hs.172648 R32170 (1) Development
(2) Transcription
34. DTNA Dystrobrevin, alpha Hs.54435 H09172 Signal transduction
35. ESTs 3978 NA Hs.6262 T89093 NA
36. EST Homo sapiens mRNA full length insert cDNA
clone EUROIMAGE 248114
Hs.8963 R33043 NA
37. ESTs Weakly similar to C44C1.2 Hs.10463 AA088448 NA
38. EST Homo sapiens clone 23808 mRNA sequence Hs.12537 R39535 NA
39. ESTs 5577 NA Hs.21124 R20560 NA
40. EST Homo sapiens cDNA FLJ20562
ﬁs, clone KAT11992
Hs.107444 H09790 NA
41. ESTs 5606 NA Hs.113137 R60530 NA
42. FEZ1 Fasciculation and elongation
protein zeta 1 (zygin I)
Hs.79226 H09157 (1) Axon guidance
(2) Cell adhesion
43. FGB Fibrinogen, B beta polypeptide Hs.7645 W94873 (1) Signal transduction
(2) Protein polymerization
44. HPCL2 2-Hydroxyphytanoyl-CoA lyase Hs.63290 R41792 Fatty acid alpha-oxidation
45. MKP-1 MAP kinase phosphatase-1 Hs.109895 NA (1) Protein dephosphorylation
(2) Cell cycle
(3) Oxidative stress
46 MPI Mannose phosphate isomerase Hs.75694 H15442 Carbohydrate metabolic process
47. MXI1 MAX-interacting protein 1 Hs.118630 AA115514 (1) Transcription
(2) Cell proliferation
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Table 2 (continued )
Genes for Gene products Hs.ID Acc. No Biological functions
48. NA1337 NA1337 NA R98174 NA
49. NCL Nucleolin Hs.79110 H05666 Angiogenesis
50. NELL1 NEL (chicken)-like 1 Hs.21602 H10041 Cell adhesion
51. OAZIN Antizyme inhibitor Hs.223014 R32814 Polyamine biosynthetic process
52. PR48 Protein phosphatase 2A 48 kDa
regulatory subunit
Hs.124942 W88679 NA
53. PSG7 Pregnancy-speciﬁc beta-1-glycoprotein 7 Hs.173609 R35240 Female pregnancy
54. PSMA6 Proteasome (prosome, macropain)
subunit, alpha type 6
Hs.74077 H06487 Ubiquitin-protein activity
55. ROR1 Receptor tyrosine kinase-like
orphan receptor 1
Hs.274243 H10667 (1) Protein phosphorylation
(2) Transmembrane receptor protein
tyrosine kinase activity
56. RPS9 Ribosomal protein S9 Hs.180920 H22514 (1) Cell proliferation
(2) Translational elongation
57. TAF1B TATA box binding protein-associated factor,
RNA polymerase I, B, 63 kDa
Hs.121044 R32478 Regulation of transcription
The Hs. ID numbers identify the genes sorted in the NCBI UniGene database in NIH, USA, whereas the Acc. No are the ofﬁcial identiﬁcation numbers for the genes stored in
databases. Gene numbers 5 (BRCA homolog), 7 (CEBPG), and 8 (E2F4) were chosen for the semiquantitative reverse transcription-polymerase chain reaction conﬁrmation on
the gene expression patterns (Fig. 4).
Acc. No ¼ accession numbers; cDNA ¼ complementary DNA; NA ¼ nonavailable.
Effects of TCHYS and LDSGT on Tumor Cells 33lines, one embryonic WRL68 cell line, and three bladder TCC T24,
TSGH-8301 and TCCSUP cell lines, were obtained from Bioresources
Collection and Research Center (Hsinchu, Taiwan). All of the cells
were routinely cultured in Dulbecco’s-modiﬁed Eagle’s medium,
supplemented with 10% fetal bovine serum, 100 U/mL penicillin,
and 100 mg/mL streptomycin (these tissue cultural reagents were
from Gibco, Grand Island, NY, USA), under 5% CO2 at 37C.
2.3. Cell viability assay and microarray hybridization
The growth rates of tumor and normal cell lines were deter-
mined by cell proliferation assay using a tetrazolium compound
and phenazine ethosulfate provided in a commercial reagent
package (CellTiter 96 AQueous One Solution Cell Proliferation Kit,
Promega; Madison, WI, USA). When performing assays, approxi-
mately 5,000 cells were seeded into the wells of 96-well culture
plates, followed by the addition of 100 mL of culture medium con-
taining various concentrations of TCHYS, LDSGT, genistein,
cisplatin, or paclitaxel, as indicated in the ﬁgures. The cells were
incubated for 72 hours before being applied to the cell proliferation
assaying reagents according to the protocol of the Kit. The
production of complementary DNA (cDNA) microarray (cDNA chip)
containing 6,371 human genes/expression sequence tags followed
the protocols described previously1113. The experiments of
proﬁling gene expression patterns were performed at least three
times with mRNA samples derived from bladder TCC TCCSUP cells
treated with 1.0 mg/mL of TCHYS or LDSGT extract individually for
0, 1, 2, 6, 12 and 24 hours. In every experiment, 4 mg of mRNA were
subjected to one-step cDNA conversion and biotin labeling, fol-
lowed by hybridizing to cDNA chips, as described previously1113.
The colorimetric detection procedure produces a blue image when
the biotin-labeled cDNA targets hybridize to human gene probes
spotted on cDNA chips. The darker the color, the higher the tran-
scriptional levels of the target genes in the cells are. The cDNA-chip
image can be computerized using a high-resolution scanner
(PowerLook 3000, UMAX; Taipei, Taiwan) and then digitized using
a Web site available (www.microarrays.org/) program ScanAlyze14.
2.4. Reverse transcription-polymerase chain reaction veriﬁcation of
gene expression patterns
Although all cDNA microarray hybridization experiments had
been performed three times to obtain the consensus lists of geneswith altered gene expression patterns (Tables 2 and 3), the
expression levels for the genes of interest were subjected to
experimental veriﬁcation by a semiquantitative reverse transcrip-
tion-polymerase chain reaction (RT-PCR) method described
earlier11,15. In the present study, the genes for BRCA2 homolog,
CEBPG (accession number AA179189) and E2F4 (accession number
R59900), which show altered expression patterns at various time
points during the treatment of TCCSUP cells with TCHYS, are
selected for the conﬁrmative experiments. The ampliﬁcation
primer sets used were (1) the BRCA2 homolog gene: 50-GTG
GCACCAAATACGAAACA-30 and 50-CCCGATACACAAACGCTGAG-30;
(2) the CEBPG gene: 50-TCGGGAATTGTGAGGTGACT-30 and 50-AACA
GCTGCAGAATGGACTT-30; and (3) the E2F4 gene: 50-GCAGGGGAA
CAGGACTCAGC-30 and 50-AGGTGGGGCCAATCATCAGG-30. In all
experiments, the ampliﬁcation of the b-Actin gene was used to
normalize the amount of RNA used. RT-PCR of these genes was
performed at the cycles when the detected amplicon molecules
were in the exponential increasing stage. After performing many
tests to correlate amounts of the PCR product with number of
thermocycles (data not shown), we used 20 ampliﬁcation cycles for
the b-Actin gene and 27 cycles for other three genes. The RT-PCR
products of the target genes were then visualized by agarose gel
electrophoresis in the presence of ethidium bromide, followed by
ﬂuorescent intensity quantiﬁcations and comparisons.
2.5. Statistical analysis
Theresultsareexpressedas themean standardderivations from
at least three experiments. Statistical comparisonswere based on the
Student t test or analysis of variance. Differences were considered
signiﬁcantly at p< 0.05. All statistical analyseswere carried out using
SigmaStat software (Jandel Scientiﬁc, San Rafael, CA, USA).
3. Results
3.1. Inhibitory effects of TCHYS and LDSGT on hepatoma cell lines
The components and the extraction procedures of TCHYS and
LDSGT were listed in Table 1 and the yield of these two drugs were
about 21.6% and 19.2%, respectively. TCHYS and LDSGT extracts
were ﬁrst tested for their growth inhibitory capability on nonma-
lignant liver epithelial (Chang Liver) and liver embryonic (WRL68),
hepatoma (HA22T/VGH, Hep3B, and HepG2) cell lines. The results
Table 3
Alternations in gene expression levels in TCCSUP cells treated with LDSGT
Genes for Gene products Hs. ID Acc. No Biological functions
Upregulated genes
1. AKT2 homolog Highly similar to Rac-beta serine/threonine kinase NA NA NA
2. BIP BiP Hs.95008 X87949 NA
3. CAPN2 Calpain, large polypeptide L2 Hs.76288 R39609 Proteolysis
4. CCT2 Chaperonin containing TCP1, subunit 2 (beta) Hs.6456 R12806 Protein folding
5. CD138 CD138 Hs.82109 NA NA
6. CDC37 CDC37 (cell division cycle 37,
Saccharomyces cerevisiae, homolog)
Hs.160958 R17767 (1) Protein targeting
(2) Cyclin-dependent protein kinase
(3) IFN-mediated signaling
7. CFTR Cystic ﬁbrosis transmembrane conductance regulator,
ATP-binding cassette (subfamily C, member 7)
Hs.663 AA515982 Respiratory gaseous exchange
8. CGI-119 CGI-119 Hs.25615 AA133459 Protein binding
9. CHI3L2 Chitinase 3-like 2 Hs.154138 T65854 Chitin catabolic process
10. CKS2 CDC28 protein kinase 2 (CKS2) mRNA NA NA (1) Cell division
(2) Cell proliferation
(3) Signal transduction
(4) Spindal organization
11. CLTA Clathrin, light polypeptide (Lca) Hs.104143 T65963 Transport
12. COL4A4 Collagen, type IV, alpha 4 Hs.180828 H68555 Strengthening of neuromuscular
junction
13. CPG2 homolog EST, highly similar to CPG2 protein Hs.43398 N23629 NA
14. CRABP1 Cellular retinoic acid-binding protein 1 Hs.7678 H92182 (1) Development
(2) Signal transduction
(3) Transport
15. CYP4F3 Cytochrome P450, subfamily IVF, polypeptide 3
(leukotriene B4 omega hydroxylase)
Hs.106242 AA099667 (1) Leukotriene metabolic process
(2) Oxidation reduction
16. DF D component of complement (adipsin) Hs.155597 AA037782 NA
17. EST NA NA AA070188 NA
18. EST NA Hs.8469 T40769 NA
19. EST Weakly similar to hypothetical protein Hs.31848 AA069144 NA
20. EST Weakly similar to RCN1_human
reticulocalbin 1 precursor
Hs.39619 H73236 NA
21. EST Weakly similar to T20B12.3 Hs.95196 H61179 NA
22. EST KIAA1285 Hs.119175 AA031699 NA
23. EST NA Hs.123069 AA043364 NA
24. EST NA Hs.193771 T95064 NA
25. EXT2 Exostoses (multiple) 2 Hs.75334 R39966 (1) Cell cycle
(2) Signal transduction
(3) Biosynthesis
(4) Ossiﬁcation
26. FKBP4 FK506-binding protein 4 (59 kDa) Hs.848 H21077 Protein folding
27. HLA-DPB1 Major histocompatibility complex, class II, DP b1 Hs.814 N23695 Antigen processing and
presentation, MHC II
28. HSD11B2 Hydroxysteroid (11-beta) dehydrogenase 2 Hs.1376 T49293 (1) Glucocorticoid biosynthesis
(2) Oxidation reduction
29. IGF2R Insulin-like growth factor 2 receptor Hs.76473 R40651 (1) Transport
(2) Signal transduction
30. ITGB1 Integrin beta-1 (ﬁbronectin receptor, beta polypeptide,
antigen CD29 includes MDF2, MSK12) mRNA
Hs.166373 NM_002211 (1) Adhesion
(2) Integrin-mediated signaling
pathway
31. IVD Isovaleryl-coenzyme A dehydrogenase Hs.77510 R38739 Oxidation reduction
32. KCNJ13 Potassium inwardly rectifying channel,
subfamily J, member 13
Hs.11364 H97186 Potassium ion transport
33. MARCKS Myristoylated alanine-rich protein kinase C substrate Hs.75607 AA031774 (1) Actin ﬁlament binding
(2) Calmodulin binding
34. MDH2 Malate dehydrogenase 2, NAD (mitochondrial) Hs.111076 H19304 (1) Glycolysis
(2) TCA cycle
(3) Oxidation reduction
35. METTL1 Methyltransferase-like 1 Hs.42957 R17664 tRNA modiﬁcation
36. MMP7 Matrix metalloproteinase 7 (matrilysin, uterine) Hs.2256 AA031514 (1) Collagen catabolism
(2) Proteolysis
37. NPM1 Nucleophosmin (nucleolar
phosphoprotein B23, numatrin)
Hs.173205 R37231 (1) Antiapoptosis
(2) Transport
(3) Signal transduction
(4) Stress
(5) Cell proliferation
38. OLFR91 homolog ESTs, moderately similar to
olfactory receptor-like protein
Hs.269151 H69005 NA
39. PFKP Phosphofructokinase, platelet Hs.99910 NA Glycolysis
40. POLR2E Polymerase (RNA) II (DNA directed)
polypeptide E (25 kD)
Hs.24301 AA031493 (1) Transcription
(2) mRNA splicing
(3) Interspecies interaction
41. PPA2267 homolog ESTs, highly similar to 6-phosphofructokinase, type C Hs.99910 NA NA
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Table 3 (continued )
Genes for Gene products Hs. ID Acc. No Biological functions
42. PRKAA2 homolog ESTs, highly similar to 50-AMP-activated
protein kinase, catalytic a2 chain
NA NA NA
43. QDPR Quinoid dihydropteridine reductase Hs.75438 R38198 (1) Metabolism
(2) Oxidation reduction
44. RAC1 Ras-related C3 botulinum toxin substrate 1
(rho family, small GTP binding protein Rac1)
Hs.173737 R37122 (1) Structure morphogenesis
(2) Cell adhesion
(3) Cell motion
(4) Signal transduction
(5) Hydrogen peroxide metabolism
45. RB1CC1 KIAA0203 gene product Hs.50421 R38102 (1) Cell cycle
(2) Transcription
46. RPL28 Ribosomal protein L28 Hs.4437 AA035400 Translational elongation
47. RPS15A Ribosomal protein S15a Hs.2953 R33435 (1) Cell cycle
(2) Cell proliferation
(3) Translational elongation
48. SERPINBS Cyclin H assembly factor NA NA Cell motion
49. STAT1 Signal transducer and activator
of transcription 1, 91 kDa
Hs.21486 AA035362 (1) IKK/NF-kB cascade
(2) Caspase activity
(3) Interspecies interaction
(4) Transcription
(5) Tyrosine phosphorylation
50. TIAF1 TGFB1-induced antiapoptotic factor 1 Hs.75822 AA035188 (1) IKK/NF-KB cascade
(2) Apoptosis
51. TPP2 Tripeptidyl peptidase II Hs.1117 R39682 Proteolysis
52. VIL2 Villin 2 (ezrin) Hs.155191 AA068995 (1) Cytoskeletal anchoring
(2) Adhesion
(3) Cell shape
53. XRCC5 X-ray repair complement defective repair
in Chinese hamster cells 5 (Ku autoantigen, 80 kDa)
Hs.84981 H17933 (1) Double-strand break repair
(2) Viral infection
(3) Telomere maintenance
54. YWHAQ Tyrosine 3-monooxygenase/tryptophan
5-monooxygenase activation
Hs.74405 H11374 Transcription
The Hs. ID numbers identify the genes sorted in the NCBI UniGene database in NIH, USA, whereas the Acc. No are the ofﬁcial identiﬁcation numbers for the genes stored in
databases.
Acc. No ¼ accession numbers; NA ¼ nonavailable; NAD ¼ nicotine adenine dinucleotide; TCA ¼ tricarboxylic acid.
Effects of TCHYS and LDSGT on Tumor Cells 35revealed that the viability of WRL68 cells remained unchanged
when being treated with 1.5 mg/mL or less of either drug, whereas
the cell viability just reduced slightly (to about 80% growth rate of
mock-treated cells) when the maximal concentration of 2.0 mg/mL
was used (Fig. 1A). On the other hand, the growths of all other liver
cell lines were mildly stimulated by TCHYS and LDSGT at low
concentrations (1.0 mg/mL or less of either drug), ranging from 110
to 130% of the mock-treated cells (Fig. 1BeE). When being treated
with drug of higher concentrations (greater than 1.5 mg/mL TCHYS
or at 2.0 mg/mL LDSGT), the growth rate of Chang Liver cells
reduced dramatically to 10e20% (Fig. 1B). In the malignant hepa-
toma or HCC cells, high concentration (2.0 mg/mL) of these two
drugs signiﬁcantly decreases the cell viability (Fig. 1CeE).
In parallel, an isoﬂavone and tyrosine protein kinase inhibitor,
genistein, which had been reported to be effective in treating
bladder tumor cells11,12,15, was used as the control agent. The data
showed inhibitory effect on WRL68 cell growth, as the cell viability
could readily be suppressed to 40% of the mock-treated cells at the
concentration greater than 20 mM (Fig. 1A). For the other liver and
hepatoma cells, Chang Liver, HA22T, and Hep3B cells, genistein at
high concentration of 80 mMhas only less than 25% inhibitory effect
(Fig. 1BeD). Furthermore, there was almost no response with
genistein treatment in hepatoma HepG2 cells (Fig. 1E).
3.2. Inhibitory effects of TCHYS and LDSGT on human bladder TCC
cell lines
In contrast to human liver and hepatoma cell lines, both TCHYS
and LDSGT had marked inhibitory effects on growth of all bladder
TCC cell lines tested in this study (Fig. 2A and B). All T24, TCCSUP,
and TSGH-8301 cell lines exhibited dose-dependent reductions in
growth rates responding to the treatments of increasingconcentrations of TCHYS or LDSGT (from 0.6 to 2.0 mg/mL), and the
levels could be reduced to less than 20% growth rate of untreated
cells. The positive control drug cisplatin can also dramatically
reduce the growth rates of all bladder TCC cell lines to less than 10%
at the concentrations of as low as 10 mg/mL (Fig. 2C). However, T24,
TCCSUP, and TSGH-8301 cells exhibited somewhat dose-dependent
growth inhibitory patterns at lower concentrations of paclitaxel,
from 0.001 to 0.1 mM.With greater amounts (>0.1 mM) added to the
culture medium, their growth rates reduced to different levels
(Fig. 2D), with the TSGH-8301 cell line being most susceptible to
the inhibition (to less than 30% growth rate of mock-treated cells),
followed by TCCSUP cells (to about 50%) and the least responsive
T24 cells (only to 80%).
3.3. Proﬁling of gene expression patterns in TCCSUP cells treated
with TCHYS or LDSGT
Among all cell lines treated with TCHYS and LDSGT, the bladder
tumor TCCSUP cell line exhibited relatively the best, most similar
growth inhibitory responses (down to about 30%) to both drugs (at
1.0 mg/mL concentrations), and was thus chosen for further
proﬁling of gene expression patterns by cDNA-chip hybridization/
colorimetric detection. Approximately 0.9% (57 genes selected in
TCHYS experiments, Table 2) and 0.8% (54 genes in LDSGT group,
Table 3) of the total 6,371 genes spotted on cDNA chip exhibited
substantial altered gene expression levels. There are 29 and 28
genes whose expression levels were induced and repressed,
respectively, when TCCSUP cells were treated with TCHYS (Fig. 3A
and B); whereas only gene expression inductions were detected, 54
of them, in LDSGT-treated cells (Fig. 3C and D). The genes identiﬁed
here may be involved in inhibiting bladder tumor cell growth that
warrants further investigation.
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Fig. 1. Growth inhibitory effects of TCHYS and LDSGT extracts on liver cell lines. Viabilities of (A) WRL68, (B) Chang Liver, (C) HA22T/VGH, (D) Hep3B, and (E) HepG2 liver cells
treated with TCHYS, LDSGT, or genistein are shown. Approximately 5,000 cells were treated with the indicated concentrations of the TCHYS or LDSGT extract (0e2.0 mg/mL) or
genistein (0e50 mM for WRL68 cells or 0e80 mM for other cell lines), followed by assaying cell growth rates. Experiments in the present study are performed at least three times,
and the results are shown as means  standard deviations. *Signiﬁcance (p < 0.05 by the t test), as the tested values are statistically compared with those of mock-treated cells for
the two drugs or cells treated with 1% DMSO, the solvent to dissolve genistein. LDSGT ¼ Long-Daan-Shiah-Gan-Tang; TCHYS ¼ Tan-Chih-Hsiao-Yao-San; DMSO.
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Fig. 2. Growth inhibitory effects of TCHYS and LDSGT extracts on bladder cell lines. Viabilities of T24, TCCSUP, and TSGH-830 bladder transitional cell carcinoma (TCC) lines treated
with (A) TCHYS, (B) LDSGT, (C) cisplatin, and (D) paclitaxel were assessed. Approximately 5,000 cells were treated with different concentrations of TCHYS, LDSGT, and the positive
control drugs cisplatin and paclitaxel, followed by cell viability assays to reveal the growth inhibitory effects. The concentrations used here are: 0e2.0 or 1.8 mg/mL with increasing
intervals of 0.2 mg/mL for the TCHYS or LDSGT extract, respectively; 0e20 mg/mL with increasing intervals of 2.0 mg/mL for cisplatin; and 0e1 mM for paclitaxel. Experiments in the
present study are performed at least three times, and the results are shown as means  standard deviations. *Signiﬁcance (p < 0.05 by the t test), as the tested values are statistically
compared with those of mock-treated cells. LDSGT ¼ Long-Daan-Shiah-Gan-Tang; TCHYS ¼ Tan-Chih-Hsiao-Yao-San.
Effects of TCHYS and LDSGT on Tumor Cells 373.4. Conﬁrmation of gene expression patterns by semiquantitative
RT-PCR assay
To verify the detected gene expressionpatterns, semiquantitative
RT-PCR was used to check the transcription levels of three genes of
interest identiﬁed previously. Fig. 4A shows that, basically, the
expression levels for the BRAC2 homolog, CEBPG, and E2F4 genes
(Gene Nos. 5, 7, and 8, respectively) are all upregulated in TCCSUP
cells by the TCHYS treatment of 0e2 hours, and then decrease. Thus,
the time-course changes detected by RT-PCR are similar to those
detectedbycDNAchips (Table2andFig. 4BeD), especiallyat theearly
time points (0e6 hours posttreatment) of drug treatment toTCCSUP
cells. These data suggest that the results obtained from cDNA
microarray proﬁling gene expression patterns are faithful.
4. Discussion
In Taiwan, the prevalence of cancers, including hepatoma and
bladder TCC, also increases rapidly, and it has become one of the
most lethal diseases in elders1. In this study, we tested the inhibi-
tory effect of TCHYS and LDSGT, two common clinically prescribed
TCM for promoting health, on the growth rates of four human liver
and three bladder tumor cell lines (Figs. 1 and 2). The purpose of
this study was to (1) examine the efﬁcacies of herbal medicineswith the current bioassay technique using the cell line model and
(2) proﬁle the gene expression patterns that may lead to the
discovery of the molecular pathway responsible for the effects of
these herbal drugs. We detected that the liver cell lines did not
respond well to the treatment of either herbal extracts at the
concentration ranges tested, whereas both drugs suppressed the
growth of all three bladder TCC cell lines in a dose-dependent
manner. In parallel, this study used several control compounds in
the same assaying methods, and one of the results indicates that
genistein and the tested TCM extracts exert their anticancer func-
tions on different regulatory pathways because both TCHYS and
LDSGT inhibited efﬁciently the growth of bladder TCC T24 cell line,
which overexpressed the oncogenic H-Ras that rendered the
resistance to the treatment of genistein15. Furthermore, the present
study also tested two other control anticancer drugs cisplatin,
which causes cross-linking of nucleic acid molecules in vivo, and
paclitaxel, which inhibits microtubules assembling, that were
manufactured to treat patients with bladder, breast, and/or other
tumors in clinics16,17. These two drugs were found to inhibit the
growth rates of the tested bladder TCC cell lines to different levels.
The mystery of TCM is that they are usually composed of many
herbal components which can only be efﬁcacious when decocted
with the appropriate amount of water or ethanol for several hours.
As one may have known, TCHYS and LDSGT each contain 10 herbs
Fig. 3. Gene expression alternations in TCCSUP cells treated with TCHYS and LDSGT. The expression-level plots of (A) upregulated genes and (B) downregulated genes in TCHYS-
treated cells. Brieﬂy, the digitalized signals for all genes on complementary DNA chips detected at six time points (0e24 hr) were compared with those at time 0 to yield the fold
changes at different time points. Panels (C) and (D) show the genes with induced expression patterns, during the treatment of bladder transitional cell carcinoma (TCC) TCCSUP cells
with LDSGT for a period of 24 hr. The identiﬁed genes, with their Gene numbers (No.) assigned in Table 2 or 3, are sequentially arranged from the higher gene expression levels to
the lower ones. LDSGT ¼ Long-Daan-Shiah-Gan-Tang; TCHYS ¼ Tan-Chih-Hsiao-Yao-San.
R.-S. Chen et al.38including three identical and seven speciﬁed herbs (Table 1); and
yet they are used to treat different as well as similar symptoms
clinically. Chaihu, Danggui, and Shanzhi are the three identical
herbs used in both TCHYS and LDSGT. Extracts from Chaihu
(Bupleuri chinese) may be effective as a therapeutic agent to treat
hepatomas only, because it increased mitochondria membrane
potential collapse in HepG2 cells, but not in lymphocytes18. Dang-
gui (Angelicae sinensis) has been reported to possess immuno-
modulatory functions, as the treatment of Danggui-containing TCM
to cancer patients, who were receiving chemotherapy and/or
radiotherapy, showed improvement in their immune functions5.
Finally, geniposide, an iridoid glucoside extracted from Shanzhi
(Gardenia jasminoides), was an effective hypoglycemic agent, by
inhibiting the hepatic glycogen phosphorylase and glucose-6-
phosphatase activities, in diabetic mice19. The Shanzhi extract has
also been reported to possess antigastritic, antioxidant, acid-
neutralizing, and anti-Helicobacter pylori activities20. It is worthy to
note that when we prepared LDSGT, Mutong (Caulis akebiae),
instead of Guamutong (Aristolochia manshuriensis Kom), was used
so as to avoid the toxic aristolochic acid produced by incorrect
processing of Guamutong11,12. In fact, described in a recently pub-
lished Chinese Internal Medicine textbook21, TCHYS is suggested
repeatedly for patients suffering from a variety of symptoms, such
as abdominal/gastric distention, poor appetite, anorexia, headache,
and irregular menstruation of dysmenorrhea for women; whereas
LDSGT is prescribed on 10 different occasions to treat illnesses
manifesting soreness of lower limbs, distending pain, insomnia,low fever, anxiety, irritability, loss of hair, and inability to have
penis erection with frequent nocturnal emission for men. There-
fore, it seems that these TCMs have versatile therapeutic applica-
tions and the molecular and cellular basis of such efﬁcacies merit
further investigation.
On examining symptoms that can be released by TCHYS and
LDSGT, many similarities are found. This remains a puzzle in our
clinical practice of TCM; how can different herbal drugs, which
comprisemanydifferent herbs, be used for treating similar illnesses.
Therefore, the present study aimed to use functional genomic
technology to assess gene expression patterns in a variety of liver
and bladder tumor cell lines treated with TCHYS and LDSGT, which
are clinical application-alike TCM and prescribed to patients
suffering from similar cancers. It is hoped that similar gene
expression patterns could be detected to account for their similar
therapeutic effects. Studies with gene chips demonstrated that
a number of genes were indeed induced to alter their gene expres-
sion levels in TCCSUP bladder tumor cells treatedwith either TCHYS
or LDSGT (Tables 2 and 3 and Fig. 3). The results provide important
information that can further be subjected to advanced functional
(anticancer) analyses. However, the gene expression patterns
obtained from treating TCCSUP cells with the two drugs produced
totally unrelated results, indicating that the data obtained here are
still insufﬁcient for a deﬁnitive conclusion; and thereforemore gene
expression proﬁling with different TCM is required to reveal the
possible common molecular pathways mediating the similar ther-
apeutic effects. Meanwhile, the genes whose expressions were
Fig. 4. Semiquantitative RT-PCR conﬁrmation of the expression patterns detected by complementary DNA microarrays. (A) Semiquantitative RT-PCR and agarose gel electrophoretic
assays on the genes for BRCA2 homolog, CEBPG, and E2F4 were performed. The comparisons of expression patterns for the (B) BRCA2 homolog, (C) CEBPG, and (D) E2F4 genes
detected by RT-PCR and microarray analysis are shown. In the present study, appropriate number of TCCSUP bladder cells were treated with 1.0 mg/mL TCHYS for indicated periods
of time (0e24 hr), followed by total RNA isolation. Then, 1.0 mg each of the RNA samples were reverse transcribed to become biotin-complementary DNA. The expression kinetics of
the three genes was subjected to semiquantitative RT-PCR analysis, and the ampliﬁcation of b-actin was used to normalize the amount of RNA used in every experiment. The RT-PCR
products were visualized by 2% agarose gel electrophoresis in the presence of ethidium bromide. Experiments in this study are performed at least three times, and all experiments
show similar results. RT-PCR ¼ reverse transcription-polymerase chain reaction; TCHYS ¼ Tan-Chih-Hsiao-Yao-San.
Effects of TCHYS and LDSGT on Tumor Cells 39altered during the treatment of TCHYS and LDSGT may be useful to
scientists who are currently working in the ﬁelds of identifying
crucial genes involved in suppressing tumor cell growths.
To verify whether the detected gene expression patterns were
reliable, semiquantitative RT-PCR was used in this study for con-
ﬁrming the transcription levels of three genes of interest identiﬁed
in TCCSUP cells treated with TCHYS (Fig. 4). The data suggest that
the results of cDNA-chip proﬁling gene expression patterns are
faithful, and thereforemicroarray technology can be readily applied
not only to gain insights into the molecular mechanism, but also to
discover the biomarkers associated with the efﬁcacies of TCM.
Biomarkers are substances used as indicators of a biologic state in
organisms, and the tumor biomarkers have now been constantly
used to evaluate the clinical performances including cures and
recurrences, and they have also become more and more important
in cancer diagnostic and prognostic assessments22. For example,
Elongation Factor 1 alpha, a pAkt-interacting protein, has been
successfully demonstrated by Pecorari et al.23 as a biomarker for
monitoring the proliferation, survival, and invasion of breast cancer
cells. Therefore, our study also initiated to set up the routine plat-
form for identifying TCM-derived tumor biomarkers using micro-
array technology and the cell line model.In summary, this report describes the testing of the efﬁcacies of
two traditional Chinese herbal medicines on liver and bladder
tumor cell lines and the proﬁling gene expression patterns in
TCCSUP cells treated with these two drugs. CHYS and LDSGT are
commonly used for promoting health and may be beneﬁcial to the
elderly with cancers who may not tolerate toxic regimens. To help
herbal drug-related functional genomics and bioinformatics
further develop and become more useful, we appeal to all scien-
tists currently conducting or having conducted microarray
researches related to Chinese herbal medicines to join forces by
comparing, combining, and posting gene expression patterns on
the public domain. Not only can this accelerate the identiﬁcation
of tumor biomarkers, but also foster the discovery of candidate
genes/pathways that mediate similar effects from different herbal
drugs.
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